ClinicalTrials.gg
CompletedNCT02676076TRIMARANUpdated Jun 26, 2026Results posted

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

A Phase 3 interventional study of CHF 5993 100/6/12.5 and CHF 1535 100/6 µg in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,155
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
4th of 66
1,155 · median 97
Started
2016
with 3 others
Phase 3
24 of 81
2 open now
Registered
44th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 4th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 44th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide [GB]) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate [FF]), with regard to lung functions parameters and rate of exacerbations as well as safety and health economics outcomes, in adult patients with uncontrolled asthma on medium doses of inhaled corticosteroids in combination with long acting ß2 agonists (LABA).

Read the detailed description

This study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines, and following all other requirements of local laws.

From screening to the end of treatment, vital signs were recorded pre-dose at screening and pre- and postdose at all visits during the treatment period; physical examination was performed at all visits; concomitant medications and adverse events (AEs) were recorded, and asthma exacerbations were assessed at all visits; lung function tests were performed (pre-dose for forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) from screening to end of treatment visits, pre-dose for inspiratory capacity and vital capacity and postdose serial spirometry at all visits during the treatment period).

Patients completed the electronic diary from home twice daily from the time of screening until the end of treatment, to record asthma symptoms, treatment compliance, and use of rescue medication. Patients used the electronic peak flowmeter to record peak expiratory flow twice daily from home from the time of screening until the end of treatment.

Asthma Control Questionnaire© (ACQ)-7 was completed at screening and all visits during the treatment period. The EuroQuality of Life-5-Dimensional-3-Level questionnaire, and health economic and outcome assessments were competed at all visits during the treatment period.

Rescue medication (salbutamol 100 μg per inhalation) was permitted throughout the treatment period when absolutely needed; the maximum allowed dose was 8 inhalations/day (800 μg).

An independent Data Safety Monitoring Board was established to provide impartial safety evaluation and assurance for patients.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma, anticholinergics, triple combination
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of asthma ≥ 1 year and diagnosed before 40 years old
  • Uncontrolled asthma with double therapy only on medium doses of Inhaled (ICS) in combination with Long-acting beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5
  • Pre-bronchodilator \<80% of the predicted normal value
  • Positive reversibility test
  • At least 1 documented asthma exacerbation in the previous year

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Diagnosis of (COPD)
  • Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening
  • Current or ex-smokers (>= 10 packs year)
  • Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,155 participants (actual)

Study arms

  • Experimental
    CHF 5993 100/6/12.5 µg

    CHF 5993 100/6/12.5 CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB BDP=Beclometasone Dipropionate bid=Twice daily FF=Formoterol Fumarate GB=Glycopyrronium Bromide

    Drug: CHF 5993 100/6/12.5

  • Active comparator
    CHF 1535 100/6 µg

    CHF 1535 100/6 µg CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF BDP=Beclometasone Dipropionate bid=Twice daily FF=Formoterol Fumarate

    Drug: CHF 1535 100/6 µg

Interventions

  • DrugCHF 5993 100/6/12.5

    BDP=Beclometasone Dipropionate 100µg; FF=Formoterol Fumarate 6µg; GB=Glycopyrronium Bromide 12.5µg.

  • DrugCHF 1535 100/6 µg

    BDP=Beclometasone Dipropionate 100µg; FF=Formoterol Fumarate 6µg.

06

What researchers measure

Primary outcomes

  1. 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26

    Change from baseline in pre-dose FEV1 was analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) to Week 26.

  2. 2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period

    Asthma exacerbation (events): Moderate AND Severe. Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

Secondary outcomes

  1. 3_Change From Baseline in Peak(0-3h) FEV1 at Week 26

    Peak FEV1 was analysed within 3 hours post-dose. FEV1=Peak of forced expiratory volume in the first second

    Time frame: Week 0 (pre-treatment, baseline) and Week 26.

  2. 4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment

    Change from baseline in the average morning PEF over the 26-Week treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26.

  3. 5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis

    Severe Asthma Exacerbation Rate over the 52-Week Treatment Period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: The entire treatment period; up to Week 52.

  4. 6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits

    Change from baseline in peak FEV1 (within 3 h post-dosing) at all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  5. 7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits

    Results show the change from baseline in pre-dose FEV1 at all clinical visits.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  6. 8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52

    Results show the percentage of patients classified as FEV1 responders at both Week 26 and Week 52. FEV1 response: Change from baseline in pre-dose morning FEV1 ≥ 100 mL.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  7. 9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits

    Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose).

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  8. 10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits

    ACQ-7 Questionnaire. Asthma Control Questionnaire-7 (ACQ-7) allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  9. 11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52

    Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent the responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and Week 52.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52

  10. 12a_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment

    Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  11. 12b_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment

    Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  12. 13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks

    Data were analysed for the number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  13. 14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

    Data were analysed for the number of patients at risk of a severe asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of patients who had a severe asthma exacerbation over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.

  14. 15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.

    Moderate asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  15. 16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

    Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  16. 17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02

    Moderate and severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate and severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  17. 18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

    Time to first moderate or severe asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate or severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  18. 19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period

    Moderate asthma exacerbation rate over the 52-Week treatment period.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  19. 20_Number of Patients at Risk of a MODERATE Asthma Exacerbation

    Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  20. 21a_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods

    Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.

  21. 21b_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period

    Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  22. 22a_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods

    Change from baseline in the percentage of rescue medication-free days in each inter-visit period over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  23. 22b_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment

    Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  24. 23a_Change From Baseline in the Average Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods

    Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  25. 23b_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period

    Results show the change from baseline in the average daily asthma symptom scores in each inter-visit period over the entire treatment. Data was collected daily through an electronic diary from screening to the end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  26. 24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods

    Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  27. 24b_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods

    Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  28. 25a_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods

    Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

  29. 25b_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period

    Results show the change from baseline in the percentage of asthma control days in each inter-visit period. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).

    Time frame: Week 0 (pre-treatment, baseline) to Week 52.

07

Results

Posted Jun 26, 2026

Participant flow

Overall, 1628 patients were screened according to inclusion and exclusion criteria; of these,1155 patients were randomised. Overall, 5 patients were randomised in error and did not start treatment (N=3 patients in the CHF 5993 pMDI 100/6/12.5 μg group and N=2 patients in the CHF 1535 pMDI 100/6 μg group). The data set Safety population, used for the evaluations represents 1150 patients.

Participant flow — Overall Study
MilestoneCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Started579576
Completed542539
Not completed3737
Withdrew: Adverse event, serious fatal30
Withdrew: Asthma exacerbation10
Withdrew: Withdrawal by subject2226
Withdrew: Protocol violation74
Withdrew: Adverse event05
Withdrew: Lost to follow-up22
Withdrew: Unknown reason not specified20

Outcome measures

Primary1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26

Change from baseline in pre-dose FEV1 was analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) to Week 26.
Reported as:
Least squares mean · Liter
1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26
LiterCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 260.185 (0.155 to 0.214)0.127 (0.098 to 0.157)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.008 · Adjusted mean difference: 0.057 · 95% CI 0.015 to 0.099
Primary2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period

Asthma exacerbation (events): Moderate AND Severe. Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · events/year
2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period
events/yearCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period1.825 (1.634 to 2.037)2.157 (1.937 to 2.402)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Negative binomial model · p = 0.033 · Adjusted rate ratio: 0.846 · 95% CI 0.725 to 0.987
Secondary3_Change From Baseline in Peak(0-3h) FEV1 at Week 26

Peak FEV1 was analysed within 3 hours post-dose. FEV1=Peak of forced expiratory volume in the first second

Time frame:
Week 0 (pre-treatment, baseline) and Week 26.
Reported as:
Least squares mean · Liter
3_Change From Baseline in Peak(0-3h) FEV1 at Week 26
LiterCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
3_Change From Baseline in Peak(0-3h) FEV1 at Week 260.485 (0.453 to 0.516)0.401 (0.369 to 0.432)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.084 · 95% CI 0.040 to 0.129
Secondary4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment

Change from baseline in the average morning PEF over the 26-Week treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26.
Reported as:
Least squares mean · Liter/min
4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment
Liter/minCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment5.325 (1.921 to 8.729)-3.131 (-6.533 to 0.271)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 8.456 · 95% CI 3.643 to 13.269
Secondary5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis

Severe Asthma Exacerbation Rate over the 52-Week Treatment Period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
The entire treatment period; up to Week 52.
Reported as:
Least squares mean · events/year
5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis
events/yearCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis0.239 (0.206 to 0.276)0.310 (0.271 to 0.354)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Negative binomial model · p = 0.008 · Adjusted rate ratio: 0.770 · 95% CI 0.636 to 0.933
Secondary6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits

Change from baseline in peak FEV1 (within 3 h post-dosing) at all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter
6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits
LiterCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Week 00.475 (0.450 to 0.500)0.422 (0.397 to 0.448)
Week 40.520 (0.490 to 0.549)0.445 (0.415 to 0.474)
Week 120.499 (0.468 to 0.529)0.437 (0.406 to 0.467)
Week 260.485 (0.453 to 0.516)0.401 (0.369 to 0.432)
Week 400.477 (0.445 to 0.509)0.385 (0.353 to 0.417)
Week 520.472 (0.439 to 0.505)0.406 (0.373 to 0.439)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.004 · Adjusted mean difference: 0.053 · 95% CI 0.017 to 0.088
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.075 · 95% CI 0.033 to 0.116
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.005 · Adjusted mean difference: 0.062 · 95% CI 0.019 to 0.105
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.084 · 95% CI 0.040 to 0.129
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.092 · 95% CI 0.047 to 0.137
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.006 · Adjusted mean difference: 0.066 · 95% CI 0.019 to 0.112
Secondary7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits

Results show the change from baseline in pre-dose FEV1 at all clinical visits.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter
7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits
LiterCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Week 40.194 (0.168 to 0.221)0.147 (0.120 to 0.173)
Week 120.195 (0.167 to 0.224)0.166 (0.138 to 0.195)
Week 260.185 (0.155 to 0.214)0.127 (0.098 to 0.157)
Week 400.188 (0.157 to 0.219)0.130 (0.099 to 0.161)
Week 520.196 (0.165 to 0.227)0.158 (0.127 to 0.189)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.013 · Adjusted mean difference: 0.048 · 95% CI 0.010 to 0.085
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.163 · Adjusted mean difference: 0.029 · 95% CI -0.012 to 0.070
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.008 · Adjusted mean difference: 0.057 · 95% CI 0.015 to 0.099
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.010 · Adjusted mean difference: 0.058 · 95% CI 0.014 to 0.101
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.096 · Adjusted mean difference: 0.038 · 95% CI -0.007 to 0.082
Secondary8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52

Results show the percentage of patients classified as FEV1 responders at both Week 26 and Week 52. FEV1 response: Change from baseline in pre-dose morning FEV1 ≥ 100 mL.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Count of participants · Participants
8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Week 26309258
Week 52306278
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Logistic model · p = 0.003 · Odds ratio (or): 1.428 · 95% CI 1.131 to 1.802
  • CHF 5993 100/6/12.5 µg · Logistic model · p = 0.104 · Odds ratio (or): 1.213 · 95% CI 0.961 to 1.530
Secondary9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits

Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose).

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter
9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits
LiterCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Week 00.362 (0.341 to 0.384)0.316 (0.295 to 0.338)
Week 40.427 (0.399 to 0.455)0.351 (0.323 to 0.379)
Week 120.411 (0.381 to 0.440)0.354 (0.324 to 0.383)
Week 260.399 (0.368 to 0.430)0.314 (0.283 to 0.345)
Week 400.387 (0.356 to 0.418)0.301 (0.271 to 0.332)
Week 520.384 (0.352 to 0.416)0.324 (0.292 to 0.356)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.003 · Adjusted mean difference: 0.046 · 95% CI 0.016 to 0.077
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.076 · 95% CI 0.037 to 0.115
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.007 · Adjusted mean difference: 0.057 · 95% CI 0.016 to 0.099
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.085 · 95% CI 0.041 to 0.129
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = < 0.001 · Adjusted mean difference: 0.086 · 95% CI 0.042 to 0.129
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.009 · Adjusted mean difference: 0.060 · 95% CI 0.015 to 0.106
Secondary10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits

ACQ-7 Questionnaire. Asthma Control Questionnaire-7 (ACQ-7) allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · score on a scale
10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits
score on a scaleCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Week 4-0.502 (-0.551 to -0.453)-0.453 (-0.502 to -0.403)
Week 12-0.592 (-0.646 to -0.539)-0.576 (-0.629 to -0.522)
Week 26-0.627 (-0.681 to -0.572)-0.584 (-0.638 to -0.529)
Week 40-0.672 (-0.729 to -0.615)-0.627 (-0.684 to -0.571)
Week 52-0.745 (-0.801 to -0.688)-0.722 (-0.779 to -0.665)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.163 · Adjusted mean difference: -0.050 · 95% CI -0.119 to 0.020
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.666 · Adjusted mean difference: -0.017 · 95% CI -0.092 to 0.059
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.274 · Adjusted mean difference: -0.043 · 95% CI -0.120 to 0.034
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.277 · Adjusted mean difference: -0.045 · 95% CI -0.125 to 0.036
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.575 · Adjusted mean difference: -0.023 · 95% CI -0.103 to 0.057
Secondary11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52

Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent the responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and Week 52.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52
Reported as:
Count of participants · Participants
11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Week 26317291
Week 52350340
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Logistic model · p = 0.129 · Odds ratio (or): 1.199 · 95% CI 0.948 to 1.517
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Logistic model · p = 0.573 · Odds ratio (or): 1.071 · 95% CI 0.848 to 1.362
Secondary12a_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment

Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · Liter/min
12a_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment
Liter/minCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
12a_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment5.845 (2.009 to 9.681)-4.406 (-8.242 to -0.571)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = <0.001 · Adjusted mean difference: 10.251 · 95% CI 4.827 to 15.676
Secondary12b_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment

Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · Liter/min
12b_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment
Liter/minCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Weeks 1-265.828 (2.330 to 9.327)-5.502 (-8.989 to -2.015)
Weeks 1-525.440 (1.622 to 9.259)-7.240 (-11.048 to -3.433)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = <0.001 · Adjusted mean difference: 11.330 · 95% CI 6.390 to 16.270
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = <0.001 · Adjusted mean difference: 12.681 · 95% CI 7.288 to 18.073
Secondary13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks

Data were analysed for the number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Count of participants · Participants
13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks337379
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Cox proportional hazards analysis · p = 0.022 · Hazard ratio (hr): 0.842 · 95% CI 0.727 to 0.975
Secondary14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

Data were analysed for the number of patients at risk of a severe asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of patients who had a severe asthma exacerbation over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
Reported as:
Count of participants · Participants
14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02209257
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Cox proportional hazards analysis · p = 0.011 · Hazard ratio (hr): 0.788 · 95% CI 0.656 to 0.946
Secondary15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.

Moderate asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · events/year
15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.
events/yearCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.1.515 (1.390 to 1.651)1.717 (1.577 to 1.869)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Negative binomial model · p = 0.043 · Adjusted rate ratio: 0.883 · 95% CI 0.782 to 0.996
Secondary16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Count of participants · Participants
16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02588663
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Cox proportional hazards analysis · p = 0.001 · Hazard ratio (hr): 0.830 · 95% CI 0.743 to 0.927
Secondary17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02

Moderate and severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate and severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · events/year
17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02
events/yearCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-021.788 (1.653 to 1.935)2.074 (1.920 to 2.241)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Cox proportional hazards analysis · p = 0.008 · Hazard ratio (hr): 0.862 · 95% CI 0.772 to 0.963
Secondary18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02

Time to first moderate or severe asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate or severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Count of participants · Participants
18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02660743
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Cox proportional hazards analysis · p = <0.001 · Hazard ratio (hr): 0.820 · 95% CI 0.739 to 0.911
Secondary19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period

Moderate asthma exacerbation rate over the 52-Week treatment period.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · events/year
19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period
events/yearCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period1.575 (1.399 to 1.773)1.821 (1.621 to 2.046)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Negative binomial model · p = 0.086 · Adjusted rate ratio: 0.865 · 95% CI 0.732 to 1.021
Secondary20_Number of Patients at Risk of a MODERATE Asthma Exacerbation

Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Count of participants · Participants
20_Number of Patients at Risk of a MODERATE Asthma Exacerbation
ParticipantsCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
20_Number of Patients at Risk of a MODERATE Asthma Exacerbation305343
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Cox proportional hazards analysis · p = 0.048 · Hazard ratio (hr): 0.856 · 95% CI 0.733 to 0.999
Secondary21a_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods

Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
Reported as:
Least squares mean · puffs/day
21a_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods
puffs/dayCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Weeks 1-26-0.475 (-0.540 to -0.410)-0.467 (-0.532 to -0.402)
Weeks 1-52-0.533 (-0.599 to -0.467)-0.537 (-0.603 to -0.471)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.862 · Adjusted mean difference: -0.008 · 95% CI -0.100 to 0.084
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.932 · Adjusted mean difference: 0.004 · 95% CI -0.089 to 0.097
Secondary21b_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period

Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · puffs/day
21b_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period
puffs/dayCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Visit 2 - Visit 3 Weeks 1-4-0.340 ± 0.825-0.372 ± 0.883
Visit 3 - Visit 4 Weeks 5-12-0.460 ± 0.998-0.468 ± 1.079
Visit 4 - Visit 5 Weeks 13-26-0.494 ± 1.103-0.527 ± 1.141
Visit 5 - Visit 6 Weeks 27-40-0.555 ± 1.132-0.616 ± 1.230
Visit 6 - Visit 7 Weeks 41-52-0.617 ± 1.217-0.625 ± 1.290
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.781 · Adjusted mean difference: 0.005 · 95% CI -0.030 to 0.040
Secondary22a_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods

Change from baseline in the percentage of rescue medication-free days in each inter-visit period over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · percentage of days
22a_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods
percentage of daysCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Weeks 1-2614.702 (12.656 to 16.747)14.723 (12.674 to 16.772)
Weeks 1-5216.377 (14.295 to 18.460)16.606 (14.519 to 18.693)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.988 · Adjusted mean difference: -0.022 · 95% CI -2.918 to 2.874
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.879 · Adjusted mean difference: 0.879 · 95% CI -3.178 to 2.720
Secondary22b_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment

Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · percentage of days
22b_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment
percentage of daysCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Visit 2 - Visit 3 Weeks 1-49.436 ± 23.34210.986 ± 25.864
Visit 3 - Visit 4 Weeks 5-1214.146 ± 29.06515.334 ± 30.671
Visit 4 - Visit 5 Weeks 13-2615.620 ± 31.06116.664 ± 33.840
Visit 5 - Visit 6 Weeks 27-4016.908 ± 31.48618.948 ± 35.215
Visit 6 - Visit 7 Weeks 41-5218.543 ± 32.48619.408 ± 36.606
Secondary23a_Change From Baseline in the Average Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods

Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · score on a scale
23a_Change From Baseline in the Average Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods
score on a scaleCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Weeks 1-26-0.161 (-0.186 to -0.136)-0.166 (-0.191 to -0.141)
Weeks 1-52-0.180 (-0.207 to -0.153)-0.194 (-0.221 to -0.167)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.781 · Adjusted mean difference: 0.005 · 95% CI -0.030 to 0.040
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.466 · Adjusted mean difference: 0.014 · 95% CI -0.024 to 0.052
Secondary23b_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period

Results show the change from baseline in the average daily asthma symptom scores in each inter-visit period over the entire treatment. Data was collected daily through an electronic diary from screening to the end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · score on a scale
23b_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period
score on a scaleCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Visit 2 - Visit 3 Weeks 1-4-0.102 ± 0.252-0.099 ± 0.275
Visit 3 - Visit 4 Weeks 5-12-0.155 ± 0.317-0.161 ± 0.349
Visit 4 - Visit 5 Weeks 13-26-0.178 ± 0.366-0.195 ± 0.379
Visit 5 - Visit 6 Weeks 27-40-0.194 ± 0.397-0.222 ± 0.416
Visit 6 - Visit 7 Weeks 41-52-0.210 ± 0.419-0.233 ± 0.435
Secondary24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods

Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · percentage of days
24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods
percentage of daysCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Weeks 1-2614.204 (12.141 to 16.267)12.690 (10.623 to 14.757)
Weeks 1-5216.847 (14.552 to 19.143)15.916 (13.615 to 18.217)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.309 · Adjusted mean difference: 1.514 · 95% CI -1.406 to 4.435
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.574 · Adjusted mean difference: 0.931 · 95% CI -2.320 to 4.182
Secondary24b_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods

Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · percentage of days
24b_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods
percentage of daysCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Visit 2 - Visit 3 Weeks 1-46.753 ± 18.2245.643 ± 18.612
Visit 3 - Visit 4 Weeks 5-1213.511 ± 26.29111.378 ± 25.671
Visit 4 - Visit 5 Weeks 13-2616.937 ± 29.66115.575 ± 30.808
Visit 5 - Visit 6 Weeks 27-4018.976 ± 33.10617.918 ± 33.121
Visit 6 - Visit 7 Weeks 41-5220.512 ± 34.12419.823 ± 35.464
Secondary25a_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods

Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Least squares mean · percentage of days
25a_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods
percentage of daysCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Weeks 1-2613.890 (11.863 to 15.916)12.132 (10.102 to 14.162)
Weeks 1-5216.395 (14.154 to 18.635)15.109 (12.863 to 17.355)
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.230 · Adjusted mean difference: 1.757 · 95% CI -1.112 to 4.626
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.427 · Adjusted mean difference: 1.286 · 95% CI -1.887 to 4.459
Secondary25b_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period

Results show the change from baseline in the percentage of asthma control days in each inter-visit period. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).

Time frame:
Week 0 (pre-treatment, baseline) to Week 52.
Reported as:
Mean · percentage of days
25b_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period
percentage of daysCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
Visit 2 - Visit 3 Weeks 1-46.869 ± 18.0665.754 ± 18.190
Visit 3 - Visit 4 Weeks 5-1213.212 ± 26.09610.908 ± 25.058
Visit 4 - Visit 5 Weeks 13-2616.495 ± 29.09614.794 ± 30.096
Visit 5 - Visit 6 Weeks 27-4018.522 ± 32.33716.919 ± 32.002
Visit 6 - Visit 7 Weeks 41-5219.802 ± 33.33018.823 ± 34.264
Statistical analysis
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.313 · Adjusted mean difference: 1.066 · 95% CI -1.007 to 3.139
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.136 · Adjusted mean difference: 2.231 · 95% CI -0.701 to 5.162
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.332 · Adjusted mean difference: 1.684 · 95% CI -1.723 to 5.092
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.541 · Adjusted mean difference: 1.164 · 95% CI -2.571 to 4.899
  • CHF 5993 100/6/12.5 µg vs CHF 1535 100/6 µg · Linear Mixed Model for Repeated Measures · p = 0.839 · Adjusted mean difference: 0.407 · 95% CI -3.529 to 4.343

Adverse events

Collected over Adverse events (AE) were reported from the time of patient informed consent signature until study completion at week 52 or at study discontinuation.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CHF 5993 100/6/12.5 µg3/576 (0.5%)28/576 (4.9%)429/576 (74.5%)
CHF 1535 100/6 µg0/574 (0%)22/574 (3.8%)451/574 (78.6%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
AsthmaRespiratory, thoracic and mediastinal disorders7/5764/574
PneumoniaInfections and infestations0/5763/574
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/5762/574
Atrial fibrillationCardiac disorders2/5760/574
Pancreatitis acuteGastrointestinal disorders2/5760/574
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5761/574
Mantle cell lymphoma stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5761/574
Hypertensive crisisVascular disorders0/5761/574
Tonsillar inflammationRespiratory, thoracic and mediastinal disorders0/5761/574
Limb crushing injuryInjury, poisoning and procedural complications0/5761/574
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCHF 5993 100/6/12.5 µgCHF 1535 100/6 µg
AsthmaRespiratory, thoracic and mediastinal disorders334/576377/574
NasopharyngitisInfections and infestations71/57678/574
HeadacheNervous system disorders38/57646/574
Respiratory tract infection viralInfections and infestations15/57626/574
BronchitisInfections and infestations18/57622/574
PharyngitisInfections and infestations12/57616/574
Viral upper respiratory tract infectionInfections and infestations12/57616/574
HypertensionVascular disorders16/5769/574
Back painMusculoskeletal and connective tissue disorders8/57614/574
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/57612/574

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
<=18 years000
Between 18 and 65 years470476946
>=65 years10698204
Age, Continuous
Age, Continuous(years)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
Mean52.6 ± 12.452.5 ± 12.252.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
Female355353708
Male221221442
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5755741149
More than one race000
Unknown or Not Reported101
Body mass index
Body mass index(kg/m^2)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
Mean27.95 ± 4.8127.92 ± 5.0727.94 ± 4.94
Body mass index - subgroups
Body mass index - subgroups(Participants)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
< 25 kg/m^2172173345
≥ 25 to < 30 kg/m^2231231462
≥ 30 kg/m^2173170343
Duration of asthma disease
Duration of asthma disease(years)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
Mean24.8 ± 12.925.2 ± 12.825.0 ± 12.8
Duration of asthma disease by group
Duration of asthma disease by group(Participants)CHF 5993 100/6/12.5 µgCHF 1535 100/6 µgTotal
< 5 years322961
5-20 years176182358
≥ 20 years368363731

7 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Chiesi Clinical Trial Site 276814
    Rostock, Germany
09

References and documents

Publications

  • Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. PubMed 31582314 ↗
  • Oba Y, Anwer S, Maduke T, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799. doi: 10.1002/14651858.CD013799.pub2. PubMed 36472162 ↗
  • Orlovic M, Magni T, Lukyanov V, Guerra I, Madoni A. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England. Respir Med. 2022 Sep;201:106934. doi: 10.1016/j.rmed.2022.106934. Epub 2022 Jul 19. PubMed 35872377 ↗
  • Papi A, Singh D, Virchow JC, Canonica GW, Vele A, Georges G. Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022 Apr 17;12(4):e12145. doi: 10.1002/clt2.12145. eCollection 2022 Apr. PubMed 35450196 ↗
  • Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020 Oct 29;21(1):285. doi: 10.1186/s12931-020-01558-y. PubMed 33121501 ↗
  • Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020 Sep 24;56(3):2000476. doi: 10.1183/13993003.00476-2020. Print 2020 Sep. No abstract available. PubMed 32430414 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol, and the full Clinical Study Report (CSR), providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared patient-level data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical trial data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in May 2018, 27 months.

Results were first posted in Jun 2026, 8 years 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2016
First posted
Feb 8, 2016
StartActual
Feb 17, 2016
Primary completionActual
May 17, 2018
CompletionActual
May 17, 2018
Results first posted
Jun 26, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02676076
Responsible party
Sponsor
First posted
Feb 8, 2016
Start date
Feb 17, 2016
Primary completion
May 17, 2018
Completion
May 17, 2018
Results posted
Jun 26, 2026
Last update
Jun 26, 2026

Study contacts

Christian Virchow, MD
principal investigator · Facharzt für Innere Medizin Rostock, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion